摘要
Burkitt淋巴瘤(BL)为儿童时期最常见淋巴瘤,占非霍奇金淋巴瘤(NHL)的30%~40%。近年,随着短疗程、高强度化疗方案应用于BL患儿的治疗,其预后显著改善,但是仍有少部分患儿于治疗中发生疾病进展或复发,并且复发/难治性BL患儿的预后极差。目前,国内外对于复发/难治性BL尚无有效、统一的治疗方案。笔者拟对BL的发病机制、儿童BL复发的影响因素、复发/难治性儿童BL的耐药机制及治疗策略等方面,综述国内外相关研究进展,旨在寻找复发/难治性儿童BL的有效治疗方案,以期提高患儿预后。
Burkitt lymphoma(BL)is the most common lymphoma in childhood,which presented 30%-40%in non-Hodgkin lymphoma(NHL).In recent years,because of using the short course,high intensity chemotherapy,the prognoses of children with BL are improved obviously.However,some cases progress or recurr during treatment.The relapse/refractory cases are still seen in a few of children,and the prognoses are very poor for them.So far,there are no useful and efficiency protocol for these relapse/refractory cases.In order to find efficacy methods for children with relapse/refractory BL,this article summaries the domestic and foreign research progress on pathogenesis,recurrence related factors,drug resistance mechanisms,and treatment strategies for children with relapsed/refractory BL,finally to improve the prognosis for children with BL.
作者
黄爽
张永红
Huang Shuang;Zhang Yonghong(Hematology Oncology Center,Capital Medical University Affiliated Beijing Children′s Hospital,Beijing 100045,China)
出处
《国际输血及血液学杂志》
CAS
2020年第5期453-456,共4页
International Journal of Blood Transfusion and Hematology
基金
北京市医院管理中心儿科学协同发展中心专项(XTZD20180204)。
关键词
儿童
伯基特淋巴瘤
复发
难治性
药物疗法
治疗结果
Child
Burkitt lymphoma
Recurrence
Refractory
Drug therapy
Treatment outcome
